276 related articles for article (PubMed ID: 37833963)
1. Mathematical Modeling Support for Lung Cancer Therapy-A Short Review.
Smieja J
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833963
[TBL] [Abstract][Full Text] [Related]
2. [Mathematical Modeling of the Intracellular Regulation of Immune Processes].
Grebennikov DS; Donets DO; Orlova OG; Argilaguet J; Meyerhans A; Bocharov GA
Mol Biol (Mosk); 2019; 53(5):815-829. PubMed ID: 31661480
[TBL] [Abstract][Full Text] [Related]
3. Mathematical modeling of intracellular signaling pathways.
Klipp E; Liebermeister W
BMC Neurosci; 2006 Oct; 7 Suppl 1(Suppl 1):S10. PubMed ID: 17118154
[TBL] [Abstract][Full Text] [Related]
4. An approach for optimally extending mathematical models of signaling networks using omics data.
Bianconi F; Patiti F; Baldelli E; Crino L; Valigi P
Annu Int Conf IEEE Eng Med Biol Soc; 2015; 2015():6501-4. PubMed ID: 26737782
[TBL] [Abstract][Full Text] [Related]
5. Integration of quantitative methods and mathematical approaches for the modeling of cancer cell proliferation dynamics.
Cotner M; Meng S; Jost T; Gardner A; De Santiago C; Brock A
Am J Physiol Cell Physiol; 2023 Feb; 324(2):C247-C262. PubMed ID: 36503241
[TBL] [Abstract][Full Text] [Related]
6. A mathematical model for microRNA in lung cancer.
Kang HW; Crawford M; Fabbri M; Nuovo G; Garofalo M; Nana-Sinkam SP; Friedman A
PLoS One; 2013; 8(1):e53663. PubMed ID: 23365639
[TBL] [Abstract][Full Text] [Related]
7. Predictive mathematical models of cancer signalling pathways.
Bachmann J; Raue A; Schilling M; Becker V; Timmer J; Klingmüller U
J Intern Med; 2012 Feb; 271(2):155-65. PubMed ID: 22142263
[TBL] [Abstract][Full Text] [Related]
8. Signal transduction pathways as novel therapy targets in lung cancer.
Reinmuth N; Mesters RM; Bieker R; Hoffknecht P; Berdel WE; Thomas M
Lung Cancer; 2004 Aug; 45 Suppl 2():S177-86. PubMed ID: 15552798
[TBL] [Abstract][Full Text] [Related]
9. Short-term information processing, long-term responses: Insights by mathematical modeling of signal transduction. Early activation dynamics of key signaling mediators can be predictive for cell fate decisions.
Schneider A; Klingmüller U; Schilling M
Bioessays; 2012 Jul; 34(7):542-50. PubMed ID: 22528856
[TBL] [Abstract][Full Text] [Related]
10. Models at the single cell level.
Cheong R; Paliwal S; Levchenko A
Wiley Interdiscip Rev Syst Biol Med; 2010; 2(1):34-48. PubMed ID: 20836009
[TBL] [Abstract][Full Text] [Related]
11. Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung Cancer.
Müller N; Lorenz C; Ostendorp J; Heisel FS; Friese UP; Cartolano M; Plenker D; Tumbrink H; Heimsoeth A; Baedeker P; Weiss J; Ortiz-Cuaran S; Büttner R; Peifer M; Thomas RK; Sos ML; Berg J; Brägelmann J
Cancer Res; 2023 Aug; 83(15):2471-2479. PubMed ID: 37289018
[TBL] [Abstract][Full Text] [Related]
12. Glutamine Addiction and Therapeutic Strategies in Lung Cancer.
Vanhove K; Derveaux E; Graulus GJ; Mesotten L; Thomeer M; Noben JP; Guedens W; Adriaensens P
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30634602
[TBL] [Abstract][Full Text] [Related]
13. Ferroptosis: A New Promising Target for Lung Cancer Therapy.
Xiong R; He R; Liu B; Jiang W; Wang B; Li N; Geng Q
Oxid Med Cell Longev; 2021; 2021():8457521. PubMed ID: 34616505
[TBL] [Abstract][Full Text] [Related]
14. Modeling cell signaling networks.
Eungdamrong NJ; Iyengar R
Biol Cell; 2004 Jun; 96(5):355-62. PubMed ID: 15207904
[TBL] [Abstract][Full Text] [Related]
15. YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib.
Garmendia I; Pajares MJ; Hermida-Prado F; Ajona D; Bértolo C; Sainz C; Lavín A; Remírez AB; Valencia K; Moreno H; Ferrer I; Behrens C; Cuadrado M; Paz-Ares L; Bustelo XR; Gil-Bazo I; Alameda D; Lecanda F; Calvo A; Felip E; Sánchez-Céspedes M; Wistuba II; Granda-Diaz R; Rodrigo JP; García-Pedrero JM; Pio R; Montuenga LM; Agorreta J
Am J Respir Crit Care Med; 2019 Oct; 200(7):888-899. PubMed ID: 31166114
[No Abstract] [Full Text] [Related]
16. The roles, controversies, and combination therapies of autophagy in lung cancer.
Wang Z; Zhou C; Yang S
Cell Biol Int; 2022 Jan; 46(1):3-11. PubMed ID: 34546599
[TBL] [Abstract][Full Text] [Related]
17. Molecular targeted agents in non-small-cell lung cancer.
Sandler AB
Clin Lung Cancer; 2003 Sep; 5 Suppl 1():S22-8. PubMed ID: 14641991
[TBL] [Abstract][Full Text] [Related]
18. Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways.
Leon G; MacDonagh L; Finn SP; Cuffe S; Barr MP
Pharmacol Ther; 2016 Feb; 158():71-90. PubMed ID: 26706243
[TBL] [Abstract][Full Text] [Related]
19. [Molecular therapy targets in lung cancer].
Le Guen Y; Sabatier L; Le Chevalier T; Soria JC
Bull Cancer; 2003 Dec; 90(12):1055-61. PubMed ID: 14715425
[TBL] [Abstract][Full Text] [Related]
20. FGFR Signaling as a Target for Lung Cancer Therapy.
Desai A; Adjei AA
J Thorac Oncol; 2016 Jan; 11(1):9-20. PubMed ID: 26762735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
